Author Correction: The repertoire of mutational signatures in human cancer.
作者信息
Alexandrov Ludmil B, Kim Jaegil, Haradhvala Nicholas J, Huang Mi Ni, Tian Ng Alvin Wei, Wu Yang, Boot Arnoud, Covington Kyle R, Gordenin Dmitry A, Bergstrom Erik N, Islam S M Ashiqul, Lopez-Bigas Nuria, Klimczak Leszek J, McPherson John R, Morganella Sandro, Sabarinathan Radhakrishnan, Wheeler David A, Mustonen Ville, Getz Gad, Rozen Steven G, Stratton Michael R
机构信息
Department of Cellular and Molecular Medicine, Department of Bioengineering, Moores Cancer Center, University of California, San Diego, CA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
出版信息
Nature. 2023 Feb;614(7948):E41. doi: 10.1038/s41586-022-05600-5.
Abstract
摘要
相似文献
1
Author Correction: The repertoire of mutational signatures in human cancer.
Nature. 2023 Feb;614(7948):E41. doi: 10.1038/s41586-022-05600-5.
2
Author Correction: One size does not fit all for mutational signatures.
Nat Cancer. 2020 Apr;1(4):469. doi: 10.1038/s43018-020-0051-5.
3
Author Correction: Mutational signatures reveal the role of RAD52 in p53-independent p21-driven genomic instability.
Genome Biol. 2022 Apr 28;23(1):107. doi: 10.1186/s13059-022-02678-y.
4
Bioinformatic Methods to Identify Mutational Signatures in Cancer.
Methods Mol Biol. 2021;2185:447-473. doi: 10.1007/978-1-0716-0810-4_28.
5
An overview of mutational and copy number signatures in human cancer.
J Pathol. 2022 Jul;257(4):454-465. doi: 10.1002/path.5912. Epub 2022 May 20.
6
Impact of cancer mutational signatures on transcription factor motifs in the human genome.
BMC Med Genomics. 2019 May 20;12(1):64. doi: 10.1186/s12920-019-0525-4.
7
Analysis of mutational signatures in C. elegans: Implications for cancer genome analysis.
DNA Repair (Amst). 2020 Nov;95:102957. doi: 10.1016/j.dnarep.2020.102957. Epub 2020 Aug 28.
8
Unraveling the genomic landscape of colorectal cancer through mutational signatures.
Adv Cancer Res. 2021;151:385-424. doi: 10.1016/bs.acr.2021.03.003. Epub 2021 Mar 27.
9
Understanding mutagenesis through delineation of mutational signatures in human cancer.
Carcinogenesis. 2016 Jun;37(6):531-40. doi: 10.1093/carcin/bgw055. Epub 2016 May 4.
10
Deciphering signatures of mutational processes operative in human cancer.
Cell Rep. 2013 Jan 31;3(1):246-59. doi: 10.1016/j.celrep.2012.12.008. Epub 2013 Jan 10.
引用本文的文献
1
Concentration-dependent effects of immunomodulatory cocktails on the generation of leukemia-derived dendritic cells, DC mediated T-cell activation and on-target/off-tumor toxicity.
Front Immunol. 2025 Jan 30;15:1527961. doi: 10.3389/fimmu.2024.1527961. eCollection 2024.
2
Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends.
Cancer Manag Res. 2024 Sep 17;16:1267-1283. doi: 10.2147/CMAR.S411023. eCollection 2024.
3
Structure-guided inhibition of the cancer DNA-mutating enzyme APOBEC3A.
Nat Commun. 2023 Oct 11;14(1):6382. doi: 10.1038/s41467-023-42174-w.
4
Using evolutionary constraint to define novel candidate driver genes in medulloblastoma.
Proc Natl Acad Sci U S A. 2023 Aug 15;120(33):e2300984120. doi: 10.1073/pnas.2300984120. Epub 2023 Aug 7.
Zotero 插件